( MENAFN - PR Newswire) SHANGHAI and HEIDELBERG, Germany, June 10, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI (The Society of Nuclear medicine and Molecular Imaging) Annual Meeting, held on June 8th to 11th, 2024 at Metro Toronto convention Centre, Toronto, ON, Canada. Neurotensin receptor 1 (NTSR1) belongs to the family of neurotensin receptors (NTSRs), which modulate the effects of the neuropeptide hormone neurotensin in several areas of the human body including the gastrointestinal system. Overexpression of NTSR1 has been associated with disease progression of multiple types of cancers, including colorectal, breast, pancreatic, and head and neck cancers.
This makes it a promising target for diagnostic imaging and radioligand therapy. In this conference, Full-Life first time disclosed the preclinical characterizations of a novel NTSR1-targeting radioligand vector FL-091, which affords favorable biodistribution profiles and encouraging anti-tumor activities for the radioisotopes it carries. In Full-Life's preclinical studies, FL-091 displayed significantly enhanced binding affinity to NTSR1 when compared to another NTSR1-targeting radioligand vector that is currently under clinical development.
Accordingly, its Lutetium-177 and Actinium-225 complexes, 177Lu-FL-091 and 225Ac-FL-091, demonstrated a mean.